Industry Research Reports
Home > Reports > Machinery & Equipment > Global Pharmacogenomics (PGx) Market Outlook, In‑Depth Analysis & Forecast to 2031
Global Pharmacogenomics (PGx) Market Outlook, In‑Depth Analysis & Forecast to 2031
Industry: Machinery & Equipment
Published Date: 2025-10-30
Pages: 142 Pages
Report ld: 5302685
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Pharmacogenomics (PGx) Market Size(US$)
CAGR 2025-2031
9.3%
Market Size,2031
USD 17,130
Million
Market Snapshot
Market Size in 2025 (Value)
US$ 10,060 million
Market Forecast in 2031(Value)
US$ 17,130 million
CAGR
9.3%
Years Considered
2020-2031
Base Year
2025
Forecast Period
2025-2031
Source: Secondary research, interviews with experts, and QYResearch analysis
The global Pharmacogenomics (PGx) market is projected to grow from US$ 9285 million in 2024 to US$ 17130 million by 2031, at a CAGR of 9.3% (2025-2031), driven by critical product segments and diverse end‑use applications.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Includes:
This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global Pharmacogenomics (PGx) market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
MARKET SEGMENTATION
By Company
- Abbott Laboratories
- Affymetrix, Inc.
- Assurex Health, Inc
- Astrazeneca
- GeneDX
- Illumina, Inc.
- Laboratory Corporation of America Holdings
- Myriad Genetics, Inc.
- Pathway Genomics
- Pfizer, Inc
- Qiagen, Inc.
- Rocheg
- Teva Pharmaceutical Industries Ltd.
- Thermo Fisher Scientific
- Transgenomic, Inc.
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Polymerase Chain Reaction (PCR)
- Microarray
- Sequencing
- Other
Segment by Application
- Cardiovascular Diseases (CVD)
- Central Nervous System (CNS)
- Cancer/Oncology
- Infectious Diseases
- Other
CHAPTER OUTLINE
Chapter 1: Defines the Pharmacogenomics (PGx) study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; top-tier players 2024 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Study Coverage
1.1 Introduction to Pharmacogenomics (PGx): Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Pharmacogenomics (PGx) Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Polymerase Chain Reaction (PCR)
1.2.3 Microarray
1.2.4 Sequencing
1.2.5 Other
1.3 Market Segmentation by Application
1.3.1 Global Pharmacogenomics (PGx) Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Cardiovascular Diseases (CVD)
1.3.3 Central Nervous System (CNS)
1.3.4 Cancer/Oncology
1.3.5 Infectious Diseases
1.3.6 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Pharmacogenomics (PGx) Revenue Estimates and Forecasts 2020-2031
2.2 Global Pharmacogenomics (PGx) Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Pharmacogenomics (PGx) Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Pharmacogenomics (PGx) Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Polymerase Chain Reaction (PCR) Market Size by Players
3.3.2 Microarray Market Size by Players
3.3.3 Sequencing Market Size by Players
3.3.4 Other Market Size by Players
3.4 Global Pharmacogenomics (PGx) Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Pharmacogenomics (PGx) Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Pharmacogenomics (PGx) Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Pharmacogenomics (PGx) Market Size by Type (2020-2031)
6.4 North America Pharmacogenomics (PGx) Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Pharmacogenomics (PGx) Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Pharmacogenomics (PGx) Market Size by Type (2020-2031)
7.4 Europe Pharmacogenomics (PGx) Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Pharmacogenomics (PGx) Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Pharmacogenomics (PGx) Market Size by Type (2020-2031)
8.4 Asia-Pacific Pharmacogenomics (PGx) Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Pharmacogenomics (PGx) Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Pharmacogenomics (PGx) Market Size by Type (2020-2031)
9.4 Central and South America Pharmacogenomics (PGx) Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Pharmacogenomics (PGx) Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Pharmacogenomics (PGx) Market Size by Type (2020-2031)
10.4 Middle East and Africa Pharmacogenomics (PGx) Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Pharmacogenomics (PGx) Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Corporation Information
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Pharmacogenomics (PGx) Product Features and Attributes
11.1.4 Abbott Laboratories Pharmacogenomics (PGx) Revenue and Gross Margin (2020-2025)
11.1.5 Abbott Laboratories Pharmacogenomics (PGx) Revenue by Product in 2024
11.1.6 Abbott Laboratories Pharmacogenomics (PGx) Revenue by Application in 2024
11.1.7 Abbott Laboratories Pharmacogenomics (PGx) Revenue by Geographic Area in 2024
11.1.8 Abbott Laboratories Pharmacogenomics (PGx) SWOT Analysis
11.1.9 Abbott Laboratories Recent Developments
11.2 Affymetrix, Inc.
11.2.1 Affymetrix, Inc. Corporation Information
11.2.2 Affymetrix, Inc. Business Overview
11.2.3 Affymetrix, Inc. Pharmacogenomics (PGx) Product Features and Attributes
11.2.4 Affymetrix, Inc. Pharmacogenomics (PGx) Revenue and Gross Margin (2020-2025)
11.2.5 Affymetrix, Inc. Pharmacogenomics (PGx) Revenue by Product in 2024
11.2.6 Affymetrix, Inc. Pharmacogenomics (PGx) Revenue by Application in 2024
11.2.7 Affymetrix, Inc. Pharmacogenomics (PGx) Revenue by Geographic Area in 2024
11.2.8 Affymetrix, Inc. Pharmacogenomics (PGx) SWOT Analysis
11.2.9 Affymetrix, Inc. Recent Developments
11.3 Assurex Health, Inc
11.3.1 Assurex Health, Inc Corporation Information
11.3.2 Assurex Health, Inc Business Overview
11.3.3 Assurex Health, Inc Pharmacogenomics (PGx) Product Features and Attributes
11.3.4 Assurex Health, Inc Pharmacogenomics (PGx) Revenue and Gross Margin (2020-2025)
11.3.5 Assurex Health, Inc Pharmacogenomics (PGx) Revenue by Product in 2024
11.3.6 Assurex Health, Inc Pharmacogenomics (PGx) Revenue by Application in 2024
11.3.7 Assurex Health, Inc Pharmacogenomics (PGx) Revenue by Geographic Area in 2024
11.3.8 Assurex Health, Inc Pharmacogenomics (PGx) SWOT Analysis
11.3.9 Assurex Health, Inc Recent Developments
11.4 Astrazeneca
11.4.1 Astrazeneca Corporation Information
11.4.2 Astrazeneca Business Overview
11.4.3 Astrazeneca Pharmacogenomics (PGx) Product Features and Attributes
11.4.4 Astrazeneca Pharmacogenomics (PGx) Revenue and Gross Margin (2020-2025)
11.4.5 Astrazeneca Pharmacogenomics (PGx) Revenue by Product in 2024
11.4.6 Astrazeneca Pharmacogenomics (PGx) Revenue by Application in 2024
11.4.7 Astrazeneca Pharmacogenomics (PGx) Revenue by Geographic Area in 2024
11.4.8 Astrazeneca Pharmacogenomics (PGx) SWOT Analysis
11.4.9 Astrazeneca Recent Developments
11.5 GeneDX
11.5.1 GeneDX Corporation Information
11.5.2 GeneDX Business Overview
11.5.3 GeneDX Pharmacogenomics (PGx) Product Features and Attributes
11.5.4 GeneDX Pharmacogenomics (PGx) Revenue and Gross Margin (2020-2025)
11.5.5 GeneDX Pharmacogenomics (PGx) Revenue by Product in 2024
11.5.6 GeneDX Pharmacogenomics (PGx) Revenue by Application in 2024
11.5.7 GeneDX Pharmacogenomics (PGx) Revenue by Geographic Area in 2024
11.5.8 GeneDX Pharmacogenomics (PGx) SWOT Analysis
11.5.9 GeneDX Recent Developments
11.6 Illumina, Inc.
11.6.1 Illumina, Inc. Corporation Information
11.6.2 Illumina, Inc. Business Overview
11.6.3 Illumina, Inc. Pharmacogenomics (PGx) Product Features and Attributes
11.6.4 Illumina, Inc. Pharmacogenomics (PGx) Revenue and Gross Margin (2020-2025)
11.6.5 Illumina, Inc. Recent Developments
11.7 Laboratory Corporation of America Holdings
11.7.1 Laboratory Corporation of America Holdings Corporation Information
11.7.2 Laboratory Corporation of America Holdings Business Overview
11.7.3 Laboratory Corporation of America Holdings Pharmacogenomics (PGx) Product Features and Attributes
11.7.4 Laboratory Corporation of America Holdings Pharmacogenomics (PGx) Revenue and Gross Margin (2020-2025)
11.7.5 Laboratory Corporation of America Holdings Recent Developments
11.8 Myriad Genetics, Inc.
11.8.1 Myriad Genetics, Inc. Corporation Information
11.8.2 Myriad Genetics, Inc. Business Overview
11.8.3 Myriad Genetics, Inc. Pharmacogenomics (PGx) Product Features and Attributes
11.8.4 Myriad Genetics, Inc. Pharmacogenomics (PGx) Revenue and Gross Margin (2020-2025)
11.8.5 Myriad Genetics, Inc. Recent Developments
11.9 Pathway Genomics
11.9.1 Pathway Genomics Corporation Information
11.9.2 Pathway Genomics Business Overview
11.9.3 Pathway Genomics Pharmacogenomics (PGx) Product Features and Attributes
11.9.4 Pathway Genomics Pharmacogenomics (PGx) Revenue and Gross Margin (2020-2025)
11.9.5 Pathway Genomics Recent Developments
11.10 Pfizer, Inc
11.10.1 Pfizer, Inc Corporation Information
11.10.2 Pfizer, Inc Business Overview
11.10.3 Pfizer, Inc Pharmacogenomics (PGx) Product Features and Attributes
11.10.4 Pfizer, Inc Pharmacogenomics (PGx) Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Qiagen, Inc.
11.11.1 Qiagen, Inc. Corporation Information
11.11.2 Qiagen, Inc. Business Overview
11.11.3 Qiagen, Inc. Pharmacogenomics (PGx) Product Features and Attributes
11.11.4 Qiagen, Inc. Pharmacogenomics (PGx) Revenue and Gross Margin (2020-2025)
11.11.5 Qiagen, Inc. Recent Developments
11.12 Rocheg
11.12.1 Rocheg Corporation Information
11.12.2 Rocheg Business Overview
11.12.3 Rocheg Pharmacogenomics (PGx) Product Features and Attributes
11.12.4 Rocheg Pharmacogenomics (PGx) Revenue and Gross Margin (2020-2025)
11.12.5 Rocheg Recent Developments
11.13 Teva Pharmaceutical Industries Ltd.
11.13.1 Teva Pharmaceutical Industries Ltd. Corporation Information
11.13.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.13.3 Teva Pharmaceutical Industries Ltd. Pharmacogenomics (PGx) Product Features and Attributes
11.13.4 Teva Pharmaceutical Industries Ltd. Pharmacogenomics (PGx) Revenue and Gross Margin (2020-2025)
11.13.5 Teva Pharmaceutical Industries Ltd. Recent Developments
11.14 Thermo Fisher Scientific
11.14.1 Thermo Fisher Scientific Corporation Information
11.14.2 Thermo Fisher Scientific Business Overview
11.14.3 Thermo Fisher Scientific Pharmacogenomics (PGx) Product Features and Attributes
11.14.4 Thermo Fisher Scientific Pharmacogenomics (PGx) Revenue and Gross Margin (2020-2025)
11.14.5 Thermo Fisher Scientific Recent Developments
11.15 Transgenomic, Inc.
11.15.1 Transgenomic, Inc. Corporation Information
11.15.2 Transgenomic, Inc. Business Overview
11.15.3 Transgenomic, Inc. Pharmacogenomics (PGx) Product Features and Attributes
11.15.4 Transgenomic, Inc. Pharmacogenomics (PGx) Revenue and Gross Margin (2020-2025)
11.15.5 Transgenomic, Inc. Recent Developments
12 Pharmacogenomics (PGx)Industry Chain Analysis
12.1 Pharmacogenomics (PGx) Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Pharmacogenomics (PGx) Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Pharmacogenomics (PGx) Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
TABLE OF FIGURES
List of Tables
Table 1. Global Pharmacogenomics (PGx) Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Pharmacogenomics (PGx) Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Pharmacogenomics (PGx) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Pharmacogenomics (PGx) Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Pharmacogenomics (PGx) Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Pharmacogenomics (PGx) Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Pharmacogenomics (PGx) Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Pharmacogenomics (PGx) by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmacogenomics (PGx) as of 2024)
Table 11. Global Pharmacogenomics (PGx) Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Pharmacogenomics (PGx) Companies Headquarters
Table 13. Global Pharmacogenomics (PGx) Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Pharmacogenomics (PGx) Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Pharmacogenomics (PGx) Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Pharmacogenomics (PGx) Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Pharmacogenomics (PGx) Revenue by Application (2026-2031) & (US$ Million)
Table 21. Pharmacogenomics (PGx) High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Pharmacogenomics (PGx) Growth Accelerators and Market Barriers
Table 25. North America Pharmacogenomics (PGx) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Pharmacogenomics (PGx) Growth Accelerators and Market Barriers
Table 27. Europe Pharmacogenomics (PGx) Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Pharmacogenomics (PGx) Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Pharmacogenomics (PGx) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Pharmacogenomics (PGx) Investment Opportunities and Key Challenges
Table 31. Central and South America Pharmacogenomics (PGx) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Pharmacogenomics (PGx) Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Pharmacogenomics (PGx) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Abbott Laboratories Corporation Information
Table 35. Abbott Laboratories Description and Major Businesses
Table 36. Abbott Laboratories Product Features and Attributes
Table 37. Abbott Laboratories Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Abbott Laboratories Revenue Proportion by Product in 2024
Table 39. Abbott Laboratories Revenue Proportion by Application in 2024
Table 40. Abbott Laboratories Revenue Proportion by Geographic Area in 2024
Table 41. Abbott Laboratories Pharmacogenomics (PGx) SWOT Analysis
Table 42. Abbott Laboratories Recent Developments
Table 43. Affymetrix, Inc. Corporation Information
Table 44. Affymetrix, Inc. Description and Major Businesses
Table 45. Affymetrix, Inc. Product Features and Attributes
Table 46. Affymetrix, Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Affymetrix, Inc. Revenue Proportion by Product in 2024
Table 48. Affymetrix, Inc. Revenue Proportion by Application in 2024
Table 49. Affymetrix, Inc. Revenue Proportion by Geographic Area in 2024
Table 50. Affymetrix, Inc. Pharmacogenomics (PGx) SWOT Analysis
Table 51. Affymetrix, Inc. Recent Developments
Table 52. Assurex Health, Inc Corporation Information
Table 53. Assurex Health, Inc Description and Major Businesses
Table 54. Assurex Health, Inc Product Features and Attributes
Table 55. Assurex Health, Inc Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Assurex Health, Inc Revenue Proportion by Product in 2024
Table 57. Assurex Health, Inc Revenue Proportion by Application in 2024
Table 58. Assurex Health, Inc Revenue Proportion by Geographic Area in 2024
Table 59. Assurex Health, Inc Pharmacogenomics (PGx) SWOT Analysis
Table 60. Assurex Health, Inc Recent Developments
Table 61. Astrazeneca Corporation Information
Table 62. Astrazeneca Description and Major Businesses
Table 63. Astrazeneca Product Features and Attributes
Table 64. Astrazeneca Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Astrazeneca Revenue Proportion by Product in 2024
Table 66. Astrazeneca Revenue Proportion by Application in 2024
Table 67. Astrazeneca Revenue Proportion by Geographic Area in 2024
Table 68. Astrazeneca Pharmacogenomics (PGx) SWOT Analysis
Table 69. Astrazeneca Recent Developments
Table 70. GeneDX Corporation Information
Table 71. GeneDX Description and Major Businesses
Table 72. GeneDX Product Features and Attributes
Table 73. GeneDX Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. GeneDX Revenue Proportion by Product in 2024
Table 75. GeneDX Revenue Proportion by Application in 2024
Table 76. GeneDX Revenue Proportion by Geographic Area in 2024
Table 77. GeneDX Pharmacogenomics (PGx) SWOT Analysis
Table 78. GeneDX Recent Developments
Table 79. Illumina, Inc. Corporation Information
Table 80. Illumina, Inc. Description and Major Businesses
Table 81. Illumina, Inc. Product Features and Attributes
Table 82. Illumina, Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Illumina, Inc. Recent Developments
Table 84. Laboratory Corporation of America Holdings Corporation Information
Table 85. Laboratory Corporation of America Holdings Description and Major Businesses
Table 86. Laboratory Corporation of America Holdings Product Features and Attributes
Table 87. Laboratory Corporation of America Holdings Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Laboratory Corporation of America Holdings Recent Developments
Table 89. Myriad Genetics, Inc. Corporation Information
Table 90. Myriad Genetics, Inc. Description and Major Businesses
Table 91. Myriad Genetics, Inc. Product Features and Attributes
Table 92. Myriad Genetics, Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Myriad Genetics, Inc. Recent Developments
Table 94. Pathway Genomics Corporation Information
Table 95. Pathway Genomics Description and Major Businesses
Table 96. Pathway Genomics Product Features and Attributes
Table 97. Pathway Genomics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Pathway Genomics Recent Developments
Table 99. Pfizer, Inc Corporation Information
Table 100. Pfizer, Inc Description and Major Businesses
Table 101. Pfizer, Inc Product Features and Attributes
Table 102. Pfizer, Inc Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Pfizer, Inc Recent Developments
Table 104. Qiagen, Inc. Corporation Information
Table 105. Qiagen, Inc. Description and Major Businesses
Table 106. Qiagen, Inc. Product Features and Attributes
Table 107. Qiagen, Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Qiagen, Inc. Recent Developments
Table 109. Rocheg Corporation Information
Table 110. Rocheg Description and Major Businesses
Table 111. Rocheg Product Features and Attributes
Table 112. Rocheg Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Rocheg Recent Developments
Table 114. Teva Pharmaceutical Industries Ltd. Corporation Information
Table 115. Teva Pharmaceutical Industries Ltd. Description and Major Businesses
Table 116. Teva Pharmaceutical Industries Ltd. Product Features and Attributes
Table 117. Teva Pharmaceutical Industries Ltd. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Teva Pharmaceutical Industries Ltd. Recent Developments
Table 119. Thermo Fisher Scientific Corporation Information
Table 120. Thermo Fisher Scientific Description and Major Businesses
Table 121. Thermo Fisher Scientific Product Features and Attributes
Table 122. Thermo Fisher Scientific Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. Thermo Fisher Scientific Recent Developments
Table 124. Transgenomic, Inc. Corporation Information
Table 125. Transgenomic, Inc. Description and Major Businesses
Table 126. Transgenomic, Inc. Product Features and Attributes
Table 127. Transgenomic, Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. Transgenomic, Inc. Recent Developments
Table 129. Raw Materials Key Suppliers
Table 130. Distributors List
Table 131. Market Trends and Market Evolution
Table 132. Market Drivers and Opportunities
Table 133. Market Challenges, Risks, and Restraints
Table 134. Research Programs/Design for This Report
Table 135. Key Data Information from Secondary Sources
Table 136. Key Data Information from Primary Sources
List of Figures
Figure 1. Pharmacogenomics (PGx) Product Picture
Figure 2. Global Pharmacogenomics (PGx) Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Polymerase Chain Reaction (PCR) Product Picture
Figure 4. Microarray Product Picture
Figure 5. Sequencing Product Picture
Figure 6. Other Product Picture
Figure 7. Global Pharmacogenomics (PGx) Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Cardiovascular Diseases (CVD)
Figure 9. Central Nervous System (CNS)
Figure 10. Cancer/Oncology
Figure 11. Infectious Diseases
Figure 12. Other
Figure 13. Pharmacogenomics (PGx) Report Years Considered
Figure 14. Global Pharmacogenomics (PGx) Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Pharmacogenomics (PGx) Revenue (2020-2031) & (US$ Million)
Figure 16. Global Pharmacogenomics (PGx) Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 17. Global Pharmacogenomics (PGx) Revenue Market Share by Region (2020-2031)
Figure 18. Global Pharmacogenomics (PGx) Revenue Market Share Ranking (2024)
Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 20. Polymerase Chain Reaction (PCR) Revenue Market Share by Player in 2024
Figure 21. Microarray Revenue Market Share by Player in 2024
Figure 22. Sequencing Revenue Market Share by Player in 2024
Figure 23. Other Revenue Market Share by Player in 2024
Figure 24. Global Pharmacogenomics (PGx) Revenue Market Share by Type (2020-2031)
Figure 25. Global Pharmacogenomics (PGx) Revenue Market Share by Application (2020-2031)
Figure 26. North America Pharmacogenomics (PGx) Revenue YoY (2020-2031) & (US$ Million)
Figure 27. North America Top 5 Players Pharmacogenomics (PGx) Revenue (US$ Million) in 2024
Figure 28. North America Pharmacogenomics (PGx) Revenue (US$ Million) by Type (2020 - 2031)
Figure 29. North America Pharmacogenomics (PGx) Revenue (US$ Million) by Application (2020-2031)
Figure 30. US Pharmacogenomics (PGx) Revenue (2020-2031) & (US$ Million)
Figure 31. Canada Pharmacogenomics (PGx) Revenue (2020-2031) & (US$ Million)
Figure 32. Mexico Pharmacogenomics (PGx) Revenue (2020-2031) & (US$ Million)
Figure 33. Europe Pharmacogenomics (PGx) Revenue YoY (2020-2031) & (US$ Million)
Figure 34. Europe Top 5 Players Pharmacogenomics (PGx) Revenue (US$ Million) in 2024
Figure 35. Europe Pharmacogenomics (PGx) Revenue (US$ Million) by Type (2020-2031)
Figure 36. Europe Pharmacogenomics (PGx) Revenue (US$ Million) by Application (2020-2031)
Figure 37. Germany Pharmacogenomics (PGx) Revenue (2020-2031) & (US$ Million)
Figure 38. France Pharmacogenomics (PGx) Revenue (2020-2031) & (US$ Million)
Figure 39. U.K. Pharmacogenomics (PGx) Revenue (2020-2031) & (US$ Million)
Figure 40. Italy Pharmacogenomics (PGx) Revenue (2020-2031) & (US$ Million)
Figure 41. Russia Pharmacogenomics (PGx) Revenue (2020-2031) & (US$ Million)
Figure 42. Asia-Pacific Pharmacogenomics (PGx) Revenue YoY (2020-2031) & (US$ Million)
Figure 43. Asia-Pacific Top 8 Players Pharmacogenomics (PGx) Revenue (US$ Million) in 2024
Figure 44. Asia-Pacific Pharmacogenomics (PGx) Revenue (US$ Million) by Type (2020-2031)
Figure 45. Asia-Pacific Pharmacogenomics (PGx) Revenue (US$ Million) by Application (2020-2031)
Figure 46. Indonesia Pharmacogenomics (PGx) Revenue (2020-2031) & (US$ Million)
Figure 47. Japan Pharmacogenomics (PGx) Revenue (2020-2031) & (US$ Million)
Figure 48. South Korea Pharmacogenomics (PGx) Revenue (2020-2031) & (US$ Million)
Figure 49. Australia Pharmacogenomics (PGx) Revenue (2020-2031) & (US$ Million)
Figure 50. India Pharmacogenomics (PGx) Revenue (2020-2031) & (US$ Million)
Figure 51. Indonesia Pharmacogenomics (PGx) Revenue (2020-2031) & (US$ Million)
Figure 52. Vietnam Pharmacogenomics (PGx) Revenue (2020-2031) & (US$ Million)
Figure 53. Malaysia Pharmacogenomics (PGx) Revenue (2020-2031) & (US$ Million)
Figure 54. Philippines Pharmacogenomics (PGx) Revenue (2020-2031) & (US$ Million)
Figure 55. Singapore Pharmacogenomics (PGx) Revenue (2020-2031) & (US$ Million)
Figure 56. Central and South America Pharmacogenomics (PGx) Revenue YoY (2020-2031) & (US$ Million)
Figure 57. Central and South America Top 5 Players Pharmacogenomics (PGx) Revenue (US$ Million) in 2024
Figure 58. Central and South America Pharmacogenomics (PGx) Revenue (US$ Million) by Type (2020-2031)
Figure 59. Central and South America Pharmacogenomics (PGx) Revenue (US$ Million) by Application (2020-2031)
Figure 60. Brazil Pharmacogenomics (PGx) Revenue (2020-2025) & (US$ Million)
Figure 61. Argentina Pharmacogenomics (PGx) Revenue (2020-2025) & (US$ Million)
Figure 62. Middle East and Africa Pharmacogenomics (PGx) Revenue YoY (2020-2031) & (US$ Million)
Figure 63. Middle East and Africa Top 5 Players Pharmacogenomics (PGx) Revenue (US$ Million) in 2024
Figure 64. South America Pharmacogenomics (PGx) Revenue (US$ Million) by Type (2020-2031)
Figure 65. Middle East and Africa Pharmacogenomics (PGx) Revenue (US$ Million) by Application (2020-2031)
Figure 66. GCC Countries Pharmacogenomics (PGx) Revenue (2020-2025) & (US$ Million)
Figure 67. Israel Pharmacogenomics (PGx) Revenue (2020-2025) & (US$ Million)
Figure 68. Egypt Pharmacogenomics (PGx) Revenue (2020-2025) & (US$ Million)
Figure 69. South Africa Pharmacogenomics (PGx) Revenue (2020-2025) & (US$ Million)
Figure 70. Pharmacogenomics (PGx) Industry Chain Mapping
Figure 71. Channels of Distribution (Direct Vs Distribution)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
What is the annual compound growth rate of the global Pharmacogenomics (PGx) market size from 2025 to 2031?
The annual compound growth rate of the global Pharmacogenomics (PGx) market is 9.3% 2025 to 2031.
What was the global market size of Pharmacogenomics (PGx) in 2031?
Which companies rank high in the global Pharmacogenomics (PGx) market?
What was the global market size of Pharmacogenomics (PGx) in 2025?
Which region is expected to have the highest market share?
Related Reports
Pharmacogenomics (PGx) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Pharmacogenomics (PGx) was estimated to be worth US$ 10060 million in 2025 and is projected to reach US$ 18570 million, growing at a CAGR of 9.3% from 2026 to 2032.
Published Date: 2026-07-15
Pages: 114
USD 3950.00
(Single User License)
Global Pharmacogenomics (PGx) Market Research Report 2026
The global Pharmacogenomics (PGx) market was valued at US$ 10060 million in 2025 and is anticipated to reach US$ 18570 million by 2032, at a CAGR of 9.3% from 2026 to 2032.
Published Date: 2026-04-28
Pages: 113
USD 2900.00
(Single User License)
Global Pharmacogenomics (PGx) Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Pharmacogenomics (PGx) market size was US$ 9285 million in 2024 and is forecast to a readjusted size of US$ 17130 million by 2031 with a CAGR of 9.3% during the forecast period 2025-2031.
Published Date: 2025-02-25
Pages: 93
USD 4250.00
(Single User License)
Pharmacogenomics (PGx)- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Pharmacogenomics (PGx) was estimated to be worth US$ 9285 million in 2024 and is forecast to a readjusted size of US$ 17130 million by 2031 with a CAGR of 9.3% during the forecast period 2025-2031.
Published Date: 2025-02-25
Pages: 105
USD 3950.00
(Single User License)
Global Pharmacogenomics (PGx) Market Research Report 2025
The global market for Pharmacogenomics (PGx) was valued at US$ 9285 million in the year 2024 and is projected to reach a revised size of US$ 17130 million by 2031, growing at a CAGR of 9.3% during the forecast period.
Published Date: 2025-02-25
Pages: 84
USD 2900.00
(Single User License)
Global Pharmacogenomics (PGx) Market Insights, Forecast to 2030
Market Analysis and Insights: Global Pharmacogenomics (PGx) Market
Published Date: 2024-04-25
Pages: 119
USD 4900.00
(Single User License)
Global Pharmacogenomics (PGx) Market Research Report 2024
The global Pharmacogenomics (PGx) market was valued at US$ 7757.9 million in 2023 and is anticipated to reach US$ 14590 million by 2030, witnessing a CAGR of 9.3% during the forecast period 2024-2030.
Published Date: 2024-01-11
Pages: 90
USD 2900.00
(Single User License)
Pharmacogenomics (PGx) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Pharmacogenomics (PGx) was estimated to be worth US$ 10060 million in 2025 and is projected to reach US$ 18570 million, growing at a CAGR of 9.3% from 2026 to 2032.
Published: 2026-07-15
Pages: 114
USD 3950.00 (Single User License)Global Pharmacogenomics (PGx) Market Research Report 2026
The global Pharmacogenomics (PGx) market was valued at US$ 10060 million in 2025 and is anticipated to reach US$ 18570 million by 2032, at a CAGR of 9.3% from 2026 to 2032.
Published: 2026-04-28
Pages: 113
USD 2900.00 (Single User License)Global Pharmacogenomics (PGx) Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Pharmacogenomics (PGx) market size was US$ 9285 million in 2024 and is forecast to a readjusted size of US$ 17130 million by 2031 with a CAGR of 9.3% during the forecast period 2025-2031.
Published: 2025-02-25
Pages: 93
USD 4250.00 (Single User License)Pharmacogenomics (PGx)- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Pharmacogenomics (PGx) was estimated to be worth US$ 9285 million in 2024 and is forecast to a readjusted size of US$ 17130 million by 2031 with a CAGR of 9.3% during the forecast period 2025-2031.
Published: 2025-02-25
Pages: 105
USD 3950.00 (Single User License)Global Pharmacogenomics (PGx) Market Research Report 2025
The global market for Pharmacogenomics (PGx) was valued at US$ 9285 million in the year 2024 and is projected to reach a revised size of US$ 17130 million by 2031, growing at a CAGR of 9.3% during the forecast period.
Published: 2025-02-25
Pages: 84
USD 2900.00 (Single User License)Global Pharmacogenomics (PGx) Market Insights, Forecast to 2030
Market Analysis and Insights: Global Pharmacogenomics (PGx) Market
Published: 2024-04-25
Pages: 119
USD 4900.00 (Single User License)Global Pharmacogenomics (PGx) Market Research Report 2024
The global Pharmacogenomics (PGx) market was valued at US$ 7757.9 million in 2023 and is anticipated to reach US$ 14590 million by 2030, witnessing a CAGR of 9.3% during the forecast period 2024-2030.
Published: 2024-01-11
Pages: 90
USD 2900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4900.00
USD 7350.00
USD 9800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now